Review ties GLP-1 blood-pressure drop to vascular and renal mechanisms
The synthesis pulls together molecular, kidney and clinical evidence behind the systolic reductions seen with GLP-1 receptor agonists.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 6 13:11 ETSource: Bioengineer.org
The wire
- 01A new review argues GLP-1 receptor agonists lower systolic blood pressure through converging vascular, cardiac and anti-inflammatory pathways rather than weight loss alone.
- 02Clinicians managing hypertensive patients on incretin therapy may find mechanistic grounding for blood-pressure changes observed in practice.
- 03The item is a narrative review, not new trial data, and the available text gives no effect sizes or trial sources.
From the source
Read at bioengineer.orgDiabetes Drugs That Quietly Lower Blood Pressure: Inside the GLP-1 Mechanism
A new review synthesizes molecular, renal and clinical evidence showing that GLP-1 receptor agonists lower systolic blood pressure through converging vascular, cardiac and anti-inflammatory mechanisms.
